149506-81-0

Basic information

• Product Name: (1r,4r)-4-(dibenzylaMino)cyclohexanol
• Synonyms: (1r,4r)-4-(dibenzylaMino)cyclohexanol
• CAS NO: 149506-81-0
• Molecular Formula: C₂₀H₂₅NO
• Molecular Weight: 295.4186
• Mol File: 149506-81-0.mol

Chemical Properties

• Boiling Point: 428.9±40.0 °C(Predicted)
• Appearance: /
• Density: 1.10±0.1 g/cm3(Predicted)
• PKA: 15.12±0.40(Predicted)
• CAS DataBase Reference: (1r,4r)-4-(dibenzylaMino)cyclohexanol(CAS DataBase Reference)
• NIST Chemistry Reference: (1r,4r)-4-(dibenzylaMino)cyclohexanol(149506-81-0)
• EPA Substance Registry System: (1r,4r)-4-(dibenzylaMino)cyclohexanol(149506-81-0)

Safety Data

• Hazardous Substances Data: 149506-81-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(1r,4r)-4-(dibenzylamino)cyclohexanol is used as a chiral building block for the synthesis of various drugs and drug intermediates. Its unique structure and chiral properties make it a valuable component in the development of new medications and therapeutic agents.
Used in Drug Development and Research:
Due to its chiral nature, (1r,4r)-4-(dibenzylamino)cyclohexanol is used in drug development and research to explore its potential therapeutic applications in the treatment of various diseases and conditions. Its pharmacological properties and potential uses make it a subject of interest in the field of medicinal chemistry and drug discovery.

Upstream product

• 27489-62-9 trans-4-hydroxycyclohexylamine 
• 100-39-0 benzyl bromide 
• 6850-65-3 p-hydroxycyclohexylamine 
• 50910-54-8 trans-4-aminocyclohexanol hydrochloride 
• 100-44-7 benzyl chloride 

Downstream Products

• 1214254-78-0 trans-4-(dibenzylamino)-1-ethylcyclohexanol 
• 1214254-25-7 4-amino-1-ethylcyclohexan-1-ol 
• 160132-95-6 tert-butyl 2-(((1r,4r)-4-(dibenzylamino)cyclohexyl)oxy)acetate 

Relevant articles and documents

CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are piperidine dione compounds having the following structure: wherein R1, R2, R3, R4, L, V, X, A, A′, a and m are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

Discovery of the c-Jun N-Terminal Kinase Inhibitor CC-90001

As a result of emerging biological data suggesting that within the c-Jun N-terminal kinase (JNK) family, JNK1 and not JNK2 or JNK3 may be primarily responsible for fibrosis pathology, we sought to identify JNK inhibitors with an increased JNK1 bias relative to our previous clinical compound tanzisertib (CC-930). This manuscript reports the synthesis and structure-activity relationship (SAR) studies for a novel series of JNK inhibitors demonstrating an increased JNK1 bias. SAR optimization on a series of 2,4-dialkylamino-pyrimidine-5-carboxamides resulted in the identification of compounds possessing low nanomolar JNK inhibitory potency, overall kinome selectivity, and the ability to inhibit cellular phosphorylation of the direct JNK substrate c-Jun. Optimization of physicochemical properties in this series resulted in compounds that demonstrated excellent systemic exposure following oral dosing, enabling in vivo efficacy studies and the selection of a candidate for clinical development, CC-90001, which is currently in clinical trials (Phase II) in patients with idiopathic pulmonary fibrosis (NCT03142191).

HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38

The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.

CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are piperidine dione compounds having the following structure: wherein RN, R1, R2, R3, R4, RN, L, V, X, a, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are piperidine dione compounds having the following structure: wherein R1, R2, R3, R4, L, V, X, a and m are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS

This invention is in the area of cell cycle inhibiting compounds for the treatment of disorders involving abnormal cellular proliferation, and include selective CDK2 inhibitors for medical therapy and their pharmaceutically acceptable salts and compositions.

TREATMENT OF CDK4/6 INHIBITOR RESISTANT NEOPLASTIC DISORDERS

This invention is to methods for treating disorders involving abnormal cellular proliferation that have developed resistance to a selective CDK4/6 inhibitor.

CRYSTALLINE SUBSTITUTED CYCLOHEXYL PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUND AND THERAPEUTIC USES THEREOF

The invention provides crystalline 5,7-dimethyl-N-((1S*,4S)-4-(pentyloxy)cyclohexyl) pyrazolo[1,5-a]pyrimidine-3-carboxamide, compositions containing the crystalline compound, methods for making the crystalline compound, medical kits, and methods for usin

HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION

This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.

1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS

A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.